Rivaroxaban: future in anticoagulation practice? - Wikidata - awgldk - TriplyDB

Rivaroxaban: future in anticoagulation practice?

Rivaroxaban: future in anticoagulation practice?

http://www.wikidata.org/entity/Q37293515

about

Rivaroxaban: future in anticoagulation practice?

http://www.wikidata.org/entity/Q37293515

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rivaroxaban: future in anticoagulation practice?

@en

Rivaroxaban: future in anticoagulation practice?

@nl

type

label

Rivaroxaban: future in anticoagulation practice?

@en

Rivaroxaban: future in anticoagulation practice?

@nl

prefLabel

Rivaroxaban: future in anticoagulation practice?

@en

Rivaroxaban: future in anticoagulation practice?

@nl

P1433

Q37293515-1B7072F9-FE8B-4EA9-9252-5F9696D13620

P1476

Q37293515-A5A15B7F-6D45-4326-BE3F-561002EFA086

P2093

Q37293515-4CD770C3-E4A5-49BF-9323-4BE27BB375F5

P2860

Q37293515-0775D564-E03A-4A4B-B14E-057EF774A26C

Q37293515-1BC766F5-6148-4002-BE9E-94BE7B08710E

Q37293515-2BF0965C-FA2D-4BC1-B747-CF2D4F046E13

Q37293515-2D069E67-93E2-41B3-912E-51690AC81468

Q37293515-30A66EA6-5E55-46B5-908F-DA0EAD226F28

Q37293515-3F4548BA-670A-4384-ACBF-A2B15E4AE66D

Q37293515-471526E0-ADF0-4F50-BC74-AB1477F4E3C0

Q37293515-7F0C9494-D5C4-4AF0-9345-C8396BDEEC45

Q37293515-84FB7D69-2193-4D5E-8A76-C2B6115E627D

Q37293515-9BF8630F-834E-41A1-B67C-60673DAA0E4B

P304

Q37293515-C8549D9F-3196-4E0E-83DF-EC1E74806440

P31

Q37293515-0DE4CD20-2A76-4BF8-A867-7FF7A4A804E5

P356

Q37293515-2996132A-2468-43EA-8AEF-8903FB881515

P433

Q37293515-0289538E-FE84-4270-919E-F832A09BF8F5

P478

Q37293515-5721CE27-12E8-40FA-9DBB-1EB4D88D3A4F

P577

Q37293515-1D1FB723-4047-4AD4-8F24-087874CF67E0

P698

Q37293515-CE2BBE0B-B6E5-49D1-A944-E7E519D5E7FE

P921

Q37293515-61201F9C-D837-4096-8548-1A0C729DCE9C

P356

102453308X343473

P1433

P1476

Rivaroxaban: future in anticoagulation practice?

@en

P2093

V Paramanathan

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

When heparins promote thrombosis: review of heparin-induced thrombocytopenia.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Targeted inhibition of coagulation: oral agents show promise in phase III trials.

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery.

P304

257-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/102453308X343473

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18854086

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation